Cargando…
P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
Autores principales: | Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171574/ http://dx.doi.org/10.1097/01.HS9.0000936308.40864.64 |
Ejemplares similares
-
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023) -
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
por: Besse, A, et al.
Publicado: (2018) -
P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA
por: Zhou, X., et al.
Publicado: (2023) -
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020) -
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
por: Hájek, R, et al.
Publicado: (2017)